Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News

Teva Engages In Settlement Talks Over Medicare Kickback Allegations

By Vandana Singh
June 18, 2:24 PM
Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copaxone sales, risking up to $10 billion in damages.

TEVA

Read More
1 minute read
  • Uncategorized

Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know

By Vaishali Prayag
June 14, 2:54 PM
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly on Korlym.

CORT

Read More
1 minute read
  • News
  • Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today

By Benzinga Insights
June 12, 1:02 PM
Teva Pharmaceutical Indus (NYSE:TEVA) has outperformed the market over the past 5 years by 2.48% on an annualized…

TEVA

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Reported Monday June 10, 2024 “Amneal, U.S. FTC Win Order Removing Teva Inhaler Patents From FDA List” – Reuters News

By Benzinga Newsdesk
June 11, 10:40 AM
https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker Amneal Pharmaceuticals (AMRX.O), opens new tab with the backing of the U.S. Federal Trade

AMRX

Read More
3 minute read
  • Analyst Ratings

4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know

By Benzinga Insights
May 30, 12:01 PM
In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish…

TEVA

Read More
3 minute read
  • Markets
  • Options

Teva Pharmaceutical Indus’s Options Frenzy: What You Need to Know

By Benzinga Insights
May 22, 12:01 PM
Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA).…

TEVA

Read More
3 minute read
  • Cannabis
  • Emerging Markets
  • Markets
  • News
  • Small Cap

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch

By Nicolas Jose Rodriguez
May 18, 10:19 AM
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

ABBV

Read More
1 minute read
  • Movers
  • News
  • Top Stories

These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio?

By Lekha Gupta
May 12, 1:33 PM
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in your portfolio?

APP

Read More
2 minute read
  • Biotech
  • Earnings
  • Equities
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher

By Vandana Singh
May 8, 1:49 PM
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed across dosing groups.

TEVA

Read More
5 minute read
  • Intraday Update
  • Markets
  • Movers
  • News

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Avi Kapoor
May 8, 1:38 PM
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday’s session after the company reported first-quarter financial results…

AFIB

Posts pagination

1 2 … 17 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service